Skip to content

Novavax NVAX Product sales — Total Revenue

Other product segments

Royalties
$3.52M

Similar metrics at other companies

Bausch Health Companies logo
BHCProduct sales — Revenue
$2.5B+12.3%
Travere Therapeutics, Inc. logo
TVTXTotal net product sales — Total Revenue
$124.49M+64.1%
TETRA Technologies logo
TTIProduct sales — Total Revenue
$83.3M-5.5%
Gilead Sciences logo
GILDProduct sales — Total revenues
$6.95B+5.0%
Amgen logo
AMGNProduct sales — Total revenues
$8.22B+4.4%
Phibro Animal Health logo
PAHCVaccines — Revenue
$38.63M+15.7%

Other financials

Income statement

See full
Revenue$139.5M-79.1%
Gross profit$108.8M-83.3%
Operating income-$15.4M-103%
Net income-$9.5M-102%
EPS (diluted)-$0.06-102%

Balance sheet

See full
Cash & equivalents$228.4M-13.3%
Total debt$295.1M+404%
Total equity-$144.8M-91.4%
Total assets$1.0B-19.3%

Cash flow

See full
Operating cash flow-$32.4M+82.5%
CapEx$1.3M-20.4%
Free cash flow-$33.7M+82.0%

Valuation

See full
Market cap$1.46B+41.0%
Enterprise value$1.53B+83.6%
P/S2.5×+1.6×

Profitability

See full
Gross margin85%-2.5pp
Operating margin-13.1%-45.9pp
Net margin-14.7%-52.9pp
FCF margin-58.9%-61.4pp

Returns & leverage

See full
Return on equity-238.6%
Debt / equity1.5×
Current ratio2.5×+0.4×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novavax's product sales — total revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Novavax's product sales — total revenue?
Novavax (NVAX) reported product sales — total revenue of $42.2M in Q1 2026.
How has Novavax's product sales — total revenue changed year-over-year?
Novavax's product sales — total revenue decreased by 93.2% year-over-year, from $621.68M to $42.2M.
What does product sales — total revenue mean?
This metric represents the total gross revenue recognized from the sale of vaccine products within the specified business segment. It serves as a primary indicator of the company's commercial success and market adoption of its clinical-stage vaccine portfolio.